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O B J E C T I V E S The aim of this study was to evaluate the relationship between percentage of
predicted left ventricular mass (%PredLVM) and valve calciﬁcation in the MESA (Multi-Ethnic Study of
Atherosclerosis) study.
B A C KG ROUND Cardiac valve calciﬁcation has been associated with left ventricular hypertrophy
(LVH), which portends cardiovascular events. However, this relationship and its mediators are poorly
understood.
METHOD S The MESA study is a longitudinal cohort study of men and women 45 to 84 years of age
without clinical cardiovascular disease in whom serial cardiac magnetic resonance and computed
tomography imaging were performed. The relationships between baseline %PredLVM and the preva-
lence, severity, and incidence of aortic valve (AVC) and mitral annulus calciﬁcation (MAC) were
determined by regression modeling.
R E S U L T S Prevalent AVC was observed in 630, and MAC was observed in 442 of 5,042 subjects
(median 55.9 and 71.1 Agatston units, respectively). After adjustment for age, sex, body mass index
(BMI), ethnicity, socioeconomic status, physical activity, diabetes, cholesterol levels, blood pressure,
smoking, kidney function, serum lipids, and antihypertensive and statin medications, %PredLVM was
associated with prevalent AVC (odds ratio [OR]: 1.18/SD increase in %PredLVM [95% conﬁdence interval
(CI): 1.08 to 1.30]; p  0.0004) and MAC (OR: 1.18 [95% CI: 1.06 to 1.32]; p  0.002). Similarly, %PredLVM
was associated with increased severity of prevalent AVC (risk difference 0.26 [95% CI: 0.15 to 0.38]; p
0.0001) and MAC (risk difference  0.20 [95% CI: 0.03 to 0.37]; p  0.02). During follow-up (mean 2.4 
0.9 years), 153 subjects (4%) developed AVC, and 198 (5%) developed MAC. The %PredLVM was
associated with incident AVC (OR: 1.24 [95% CI: 1.04 to 1.47]; p  0.02) and MAC (OR: 1.18 [95% CI: 1.01
to 1.40]; p 0.04). Further adjustment for inﬂammatory markers and coronary artery calciﬁcation did not
attenuate these associations. Speciﬁcally, concentric LVH most strongly predicted incident valve
calciﬁcation.
CONC L U S I O N S Within the MESA cohort, LVH was associated with prevalence, severity, and
incidence of valve calciﬁcation independent of hypertension and other identiﬁed confounders. (J Am
Coll Cardiol Img 2012;5:781–8) © 2012 by the American College of Cardiology Foundation
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782alcification of the aortic and mitral valves
is a progressive disease similar to athero-
sclerosis (1–4) that is associated with ad-
verse cardiovascular outcomes (5–7). Even
ithout hemodynamically significant valve obstruc-
ion, calcific aortic and mitral valve disease have been
ssociated with dramatic increases in the risk of
yocardial infarction, stroke, and cardiovascular and
ll-cause mortality (5–7). Valve calcification might be
marker of atherosclerosis, but discordance between
oronary disease and calcific valve disease suggests that
lternative mechanisms such as inflammation, neuro-
ormonal activation, endothelial dysfunction, or other
enetic factors also might play a role (1–4).
Aortic stenosis (AS) causes compensatory left
entricular hypertrophy (LVH); however, 2 small
cross-sectional analyses suggest an associ-
ation between aortic valve disease and
LVH in the absence of significant valve
obstruction (3,8). Although LVH in this
setting might be a consequence of low
levels of outflow obstruction, similar asso-
ciations between LVH and prevalent mi-
tral annulus calcification (MAC) suggest
that alternate processes might lead to both
valvular calcification and left ventricular
(LV) remodeling (9,10). The longitudinal
MESA (Multi-Ethnic Study of Athero-
sclerosis) study provides a unique oppor-
tunity to explore relationships between
LVH and calcific valve disease.
M E T H O D S
Study population and data collection. The
MESA study is a prospective cohort study
of 6,814 men and women 45 to 84 years of
ge recruited from 6 U.S. communities designed to
valuate risk factors for cardiovascular disease. At
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11). This analysis was limited to the 5,042 subjects
ho underwent cardiac magnetic resonance and
omputed tomography (CT).
Measurement of cardiovascular calciﬁcation. Aortic
valve and mitral annulus calcification were assessed
by electron-beam CT at 3 centers and by multi-
detector row helical CT at 3 centers. All studies
were interpreted centrally (Los Angeles Biomedical
Research Institute at Harbor-UCLA, Torrance,
California). Calcification was quantified by Agat-
ston scoring (12). Prevalent cardiovascular calcifi-
cation was defined as a score 0 Agatston units
(AU). Details of the image acquisition and inter-
pretation protocols, quality control measures, and
interobserver reliability characteristics have been
reported previously (13). Follow-up cardiac CT
scans with assessment of aortic valve calcification
(AVC) and MAC were performed 2 to 3 years after
the initial scan.
Determination of LV mass. Magnetic resonance im-
aging was performed with 1.5-T magnets with
4-element phased-array surface coils, electrocardio-
graphic gating, and blood pressure monitoring. The
LV mass was quantified as previously described
(14). With an allometric approach, regression mod-
els for body size were derived from a sample of
1,746 MESA participants without obesity, hyper-
tension, antihypertensive medication, diabetes, im-
paired fasting glucose, or hypoglycemic medication,
and a multiplicative estimate was derived from the
regression of log(LV mass) on log(height), log-
(weight), and sex. The LV mass was adjusted for body
size by dividing LV mass by the predicted LV mass on
the basis of height, weight, and sex as: 100 · LV
mass/(a · height0.54 · weight0.61), where a  6.82 for
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783women and 8.25 for men with mass in grams,
height in meters, and weight in kilograms (15).
Similarly, LV end-diastolic volume was adjusted for
body size and sex by dividing by the predicted LV
volume as: 100 · LV end-diastolic volume/(b ·
height1.25 · weight0.43), where b  10.0 for women
and 10.5 for men. The resultant percentage of
predicted LV mass (%PredLVM) and percentage of
predicted LV end diastolic volume (%LVVol) were
used for all analyses.
Covariates. Historical data were collected with a
combination of self- and interviewer-administered
questionnaires. Smoking status was defined as cur-
rent, former, or never, with current smoking de-
fined as smoking a cigarette in the last 30 days.
Diabetes was defined as a fasting glucose 126
mg/dl or hypoglycemic medication use. Hyperten-
sion was defined as systolic blood pressure 140
mm Hg, diastolic blood pressure 90 mm Hg, a
reported history of hypertension, or antihyperten-
sive therapy. Estimated glomerular filtration rate
(eGFR) was calculated with the Modification of
Diet in Renal Disease equation. Physical activity
was assessed with the MESA Typical Week Phys-
ical Activity Survey and quantified for this analysis
as minutes of vigorous activity/week multiplied by
metabolic equivalent level (16).
Statistical analysis. Differences in patient character-
istics across %PredLVM strata were evaluated with
analysis of variance. Chi-square analyses were used
for categorical variables. To approximate a normal
distribution, calcium scores were log-transformed
for use in analyses of severity. Logistic regression
was used to derive odds ratios (ORs) for the
relationships between baseline %PredLVM and the
prevalence and incidence of AVC and MAC. Lin-
ear regression models with log-transformed valve
calcium scores were used to assess relationships
between %PredLVM and severity of AVC and
MAC in subjects with prevalent disease. Statistical
analyses were performed with SAS (version 9.2,
SAS Institute, Inc., Cary, North Carolina), with
significance accepted at p  0.05.
R E S U L T S
Subject characteristics. A total of 5,042 subjects
nderwent both cardiac CT and magnetic reso-
ance imaging scans, with a mean age of 62  10
ears; 46% were men (Table 1). The mean end-
iastolic LV mass was 145  40 g. The mean
PredLVM, which adjusts for body size and sex,
as 104  19%, indicating the LV mass of theopulation was 4% greater than the reference cohort
f participants without obesity, hypertension, anti-
ypertensive medication, diabetes, impaired fasting
lucose or hypoglycemic medication. Quartiles of
PredLVM were defined as: quartile 1: 91.5%,
uartile 2: 91.5% to 102.2%, quartile 3: 102.2% to
14.6%, quartile 4 114.6% (Table 1). The pro-
ortion of subjects with diabetes mellitus, hyper-
ension, and current smoking status increased by
PredLVM quartile. Significant ethnic variation in
V mass were observed with greater %PredLVM
bserved in Blacks and Hispanics (Table 1).
LV mass and prevalent valve calcium. At the baseline
valuation, cardiac CT identified AVC in 630
ubjects (13%) and MAC in 442 (9%). Both AVC
nd MAC were observed in 183 (4%) subjects.
tratification by %PredLVM quartile demonstrated
ncreasing prevalence of valve calcification with
ncreasing %PredLVM, with AVC observed in 144
ubjects (11%) in the lowest and 200 (15%) in the
ighest %PredLVM quartiles (p  0.0004) and
AC observed in 97 subjects (8%) in the lowest
PredLVM quartile and 134 (11%) in the highest
uartile (p  0.049) (Fig. 1A). This relationship
as consistent across ethnic groups within MESA
or both AVC and MAC (Figs. 1B and 1C). After
djusting by multivariable analysis for age, sex,
MI, ethnicity, study site, socioeconomic status,
hysical activity, diabetes, history of hypercholes-
erolemia, hypertension, smoking, eGFR, total se-
um cholesterol and low-density lipoprotein-
holesterol levels, systolic and diastolic blood
ressures, and use of antihypertensive agents and
tatins, %PredLVM was associated with prevalent
VC (OR: 1.18/SD increase in %PredLVM [95%
I: 1.08 to 1.30]; p  0.0004) and MAC (OR:
.18 [95% CI: 1.06 to 1.32]; p  0.002).
LV mass and the severity of valve calcium. Among
those subjects with valve calcium at baseline, the
median AVC score was 55.9 (interquartile range:
21.0 to 149.1) AU, and the median MAC score was
71.1 (22.4 to 290.2) AU. The severity of both AVC
and MAC, defined as log (Agatston score), in-
creased with increasing quartile of %PredLVM
(AVC, mean [SD]: 3.7 [1.3], 4.0 [1.3], 4.1 [1.5],
4.3 [1.7], respectively; p  0.01; MAC: 4.3 [1.9],
4.2 [1.8], 4.5 [1.9], 4.8 [1.8], respectively; p 
0.055). Multivariable regression analyses adjusting
for the aforementioned variables demonstrated a
robust relationship between %PredLVM and the
severity of AVC (risk difference 0.26/SD increase
in %PredLVM [95% CI: 0.15 to 0.38]; p 0.0001)
fs
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784and MAC (risk difference  0.20 [95% CI: 0.03 to
0.37]; p  0.02).
LV mass and incident valve calcium. Over a mean
racteristics Stratiﬁed by Quartile of %PredLVM
Total
(n  5,042)
Quartile 1
(<91.5%)
(n  1,260)
Quartile 2
(91.5%–102.2
(n  1,261)
62 10 62 10 61 10
2,316 (46) 596 (47) 576 (46)
1,952 (39) 575 (46) 505 (40)
1,247 (25) 257 (20) 272 (22)
1,135 (23) 247 (20) 274 (22)
708 (14) 181 (14) 210 (17)
28 5 28 5 28 5
1.8 0.2 1.9 0.2 1.8 0.2
/dl
195 36 198 38 196 35
117 31 119 33 117 30
52 15 51 16 51 15
115 (81–167) 121 (85–171) 119 (84–170)
654 (13) 133 (11) 143 (11)
1,859 (37) 463 (37) 497 (40)
1,468 (29) 263 (21) 303 (24)
81 17 80 16 80 16
1,790 (36) 476 (38) 452 (36)
627 (12) 110 (9) 131 (10)
593 (12) 108 (9) 123 (10)
463 (9) 92 (7) 90 (7)
622 (12) 90 (7) 119 (9)
683 (14) 159 (13) 150 (12)
226 (4) 42 (3) 47 (4)
e 1,639 (33) 319 (25) 355 (28)
748 (15) 187 (15) 200 (16)
788 (16) 220 (38) 180 (30)
g
72 10 70 10 70 9
125 21 119 19 122 19
93 13 90 12 91 12
63 9 65 9 63 9
145 40 117 25 135 27
104 19 83 8 97 3
126 31 113 26 122 27
101 19 90 16 98 15
io 1.17 0.24 1.06 0.21 1.12 0.22
69 7 70 7 70 7
(%), or median (interquartile range). *Self-reported history of hypertension.
f predicted left ventricular end-diastolic volume; %PredLVM  percentage of pr
ocker; eGFR  estimated glomerular ﬁltration rate; HDL  high-density lipoprote
ntricular end-diastolic; LVEF  left ventricular ejection fraction; LVeS  left ventollow-up of 2.4  0.9 years, 153 (4%) of 3,902 (ubjects without AVC at baseline developed AVC,
n annualized incidence rate of 1.6%. Of the 4,072
ubjects without MAC at the first evaluation, 198
Quartile 3
(102.2%–114.6%)
(n  1,261)
Quartile 4
(>114.6%)
(n  1,260) p Value
61 10 62 10 0.05
567 (45) 577 (46) 0.69
0.0001
478 (38) 394 (31)
323 (26) 395 (31)
267 (21) 347 (28)
193 (15) 124 (10)
27 5 28 5 0.55
1.8 0.2 1.8 0.2 0.03
194 35 194 37 0.05
116 31 116 32 0.06
52 15 52 15 0.28
113 (80–159) 109 (76–163) 0.0001
166 (13) 212 (17) 0.0001
437 (35) 462 (37) 0.11
391 (31) 511 (41) 0.0001
82 18 82 19 0.0002
462 (37) 400 (32) 0.001
142 (11) 244 (19) 0.0001
144 (11) 218 (17) 0.0001
126 (10) 155 (12) 0.0001
181 (14) 232 (18) 0.0001
168 (13) 206 (16) 0.01
59 (5) 78 (6) 0.005
427 (34) 538 (43) 0.0001
178 (14) 183 (15) 0.65
213 (35) 175 (27) 0.0005
72 10 75 11 0.0001
125 20 134 24 0.0001
93 13 99 15 0.0001
62 9 61 10 0.0001
150 32 179 42 0.0001
108 4 129 15 0.0001
128 30 140 36 0.0001
103 16 113 22 0.0001
1.18 0.22 1.30 0.26 0.0001
69 7 67 9 0.0001
ted left ventricular mass; BMI  body mass index; BSA  body surface area;
RT  hormone replacement therapy; LDL  low-density lipoprotein; LV  left
r end-systolic; RAS  renin-angiotensin system.Table 1. Baseline Cha
%)
Age, yrs
Male
Race
White
Black
Hispanic
Chinese
BMI, kg/m2
BSA, m2
Serum cholesterol, mg
Total cholesterol
LDL-cholesterol
HDL-cholesterol
Triglycerides
Diabetes mellitus
Hyperlipidemia
Hypertension*
eGFR, ml/min/1.73 m2
Smoking status
Former
Current
Concurrent medication
RAS inhibitor
Beta-blocker
CCB
Diuretic
Vasodilator
Any antihypertensiv
Statin
HRT
Blood pressure, mm H
Diastolic
Systolic
Mean
Heart rate, beats/min
LV measurements
LVeD mass, g
%PredLVM, %
LVeD volume, ml
%LVVol, %
LV mass/volume rat
LVEF, %
Values are mean  SD, n
%LVVol  percentage o edic
CCB  calcium channel bl in; H
ventricular; LVeD  left ve ricula5%) developed MAC during follow-up, an inci-
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785dence rate of 2.0%/year. We found a relationship
between incident AVC and baseline %PredLVM
(incidence rate 1.2%/year in the lowest quartile and
1.9%/year in the highest quartile; p  0.05)
(Fig. 2). Incident MAC was significantly greater
among subjects in the highest %PredLVM quartile
than in the lowest quartile (2.9%/year vs. 1.9%/year;
p  0.03).
Because of the racial variations in LV mass and
valve calcification and the interaction of age with
risk factors for valve calcification (17–19), we tested
for interactions between race and age with
%PredLVM for incident valve calcification. Neither
race nor age demonstrated significant interactions
with %PredLVM for AVC (race: Chinese p 
0.43, Black p  0.98, Hispanic p  0.20, each vs.
aucasian ethnicity; age: p  0.63) or MAC (race:
hinese p  0.97, Black p  0.41, Hispanic p 
.98, each vs. Caucasian ethnicity; age: p  0.20).
fter adjustment for age, sex, ethnicity, and study
ite, %PredLVM was significantly associated with
ncident AVC (OR: 1.20/SD increase in
PredLVM [95% CI: 1.02 to 1.40]; p  0.03) and
ncident MAC (OR: 1.16 [95% CI: 1.00 to 1.35];
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Figure 1. Relationship of LV Mass to Prevalent Valve Calciﬁcatio
Unadjusted prevalence of aortic valve (AVC) and mitral annulus calc
left ventricular (LV) mass (%PredLVM). 0.049). Sequential multivariable models wereonstructed in an effort to identify mediators of this
elationship (Table 2). Additional adjustments for
ardiovascular risk factors including BMI, diabetes,
ypercholesterolemia, hypertension, smoking,
GFR, cholesterol, blood pressure, antihypertensive
r statin therapy, socioeconomic status, physical
ctivity, inflammatory markers (serum interleukin
3
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Figure 2. Relationship of LV Mass to Incident Valve Calciﬁcation
Unadjusted incidence of AVC and MAC stratiﬁed by quartile of perc
left ventricular (LV) mass (%PredLVM) demonstrates that increased
line evaluation is associated with the development of incident valv
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786[IL]-6, high-sensitivity C-reactive protein [hs-
CRP]), and coronary artery calcification as a mea-
sure of subclinical atherosclerosis did not eliminate
the association between %PredLVM and incident
AVC (OR: 1.23/SD increase in %PredLVM [95%
CI: 1.03 to 1.46]; p 0.02) or incident MAC (OR:
.19 [95% CI: 1.01 to 1.40]; p  0.04).
We subsequently evaluated parameters of LV
geometry. After adjusting for age, sex, BMI, eth-
nicity, study site, socioeconomic status and physical
activity, %PredLVM and the LV mass/volume ratio
were associated with both incident AVC and MAC
(Table 3). Concentric LVH, defined by LV mass/
volume ratio, was the strongest predictor of incident
valve calcification (AVC: OR: 1.21/SD increase
[95% CI: 1.03 to 1.43]; p  0.02; MAC: OR: 1.27
[95% CI: 1.09 to 1.47]; p  0.002]; whereas, there
as no relationship between percentage of pre-
icted LV volume and either AVC or MAC.
D I S C U S S I O N
The association of increasing LV mass with the
prevalence and severity of AVC is aligned with the
paradigm that LVH develops in response to aortic
of Increased LV Mass With Incident Valve Calciﬁcation
OR 95% CI p Value
n (n  4,412)
1.20 1.02–1.40 0.03
1.24 1.04–1.47 0.02
1.24 1.04–1.47 0.02
1.23 1.03–1.46 0.02
tion (n  4,600)
1.16 1.00–1.35 0.049
1.17 1.00–1.38 0.04
1.18 1.01–1.39 0.04
1.19 1.01–1.40 0.04
are per SD increase in %PredLVM. *Adjusted for age, sex, ethnicity, and study
1 variables plus presence of BMI, diabetes, hypercholesterolemia, or hyperten-
R, serum total and LDL-cholesterol levels, and systolic and diastolic blood
hypertensive agents and statins. ‡Adjusted for Model 2 variables plus income
tatus, and physical activity. §Adjusted for Model 3 variables plus natural
artery calciﬁcation score  1), interleukin-6, and C-reactive protein.
other abbreviations as in Table 1.
Table 3. Relationship of Left Ventricular Parameters to Incident
Aortic Valve Calciﬁ
OR 95% CI
%PredLVM 1.21 1.04–1.42
%LVVol 1.00 0.84–1.18
LV mass/volume ratio, g/ml 1.21 1.03–1.43
Odds ratios depicted are per 1 SD increase. Models adjust for age, sex, BMI, et
Abbreviations as in Tables 1 and 2.valve disease. However, we also found associations
between LV mass and the prevalence and severity of
MAC, which does not increase LV afterload and
has not been recognized as an independent cause of
LVH. Furthermore, we demonstrate that increased
LV mass, specifically concentric and noneccentric
LVH, independently predicts the development of
AVC and MAC over time. These observations
suggest that concentric LVH might identify sub-
jects at risk for valve calcification and possibly that
common pathophysiological mechanisms might ac-
count for both the development of valvular calcifi-
cation and LVH.
An obvious potential explanation for this associ-
ation is hypertension, which has been consistently
implicated as a factor in the development and
progression of calcific valve disease (1,2,20) and is
the most common cause of LVH in the general
population (21). Hypertension, broadly defined on
the basis of patient reporting, increased systolic or
diastolic blood pressure on the initial study visit, or
the use of any antihypertensive therapy was preva-
lent among 2,281 subjects in the MESA cohort
(45%). Multivariable analyses adjusting for hyper-
tension suggest that the observed relationships be-
tween LVH and valve calcification are independent
of this factor; however, residual confounding by
hypertension cannot be excluded. More sensitive
measures of hypertension, such as ambulatory blood
pressure monitoring, would be necessary to more
definitively exclude hypertension as a mediator of
the observed relationships.
Inflammatory and neurohormonal mechanisms
have also been implicated in the development of
both cardiovascular calcification and LVH. Angio-
tensin II and several inflammatory cytokines are
involved in both myocardial remodeling and valve
calcification, and any or all of these could mediate
the relationship between %PredLVM and incident
valve calcification (1,2,22–25). Exploring potential
links, we adjusted for cardiovascular risk factors, the
inflammatory markers hs-CRP and IL-6, and sub-
clinical atherosclerosis by sequential multivariable
lve Calciﬁcation
on Mitral Annulus Calciﬁcation
p Value OR 95% CI p Value
0.02 1.18 1.02–1.37 0.03
0.95 0.89 0.75–1.04 0.14
0.02 1.27 1.09–1.47 0.002
ty, and study site.Table 2. Association
Aortic valve calciﬁcatio
Model 1*
Model 2†
Model 3‡
Model 4§
Mitral annulus calciﬁca
Model 1*
Model 2†
Model 3‡
Model 4§
Odds ratios (ORs) depicted
site. †Adjusted for Model
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787analyses and found no attenuation of the association
between LVH and valve calcification, suggesting
that none of these factors entirely explains the
relationship. However, we did not possess measures
of other neurohormonal and inflammatory path-
ways. Alternatively, valve remodeling, inflamma-
tion, and calcification have been linked to changes
in the hemodynamic environment. Conceivably,
LVH-associated alterations in shear stress and cy-
clic pressures and stretch might induce or prop-
agate valve pathology (26,27). Regardless of the
etiology, our analyses suggest that concentric
LVH identifies those subjects at risk for devel-
oping valve calcification.
Study limitations. First is the limited power to fully
valuate factors that are associated with valve calci-
cation and LVH, given the relative good health of
he MESA cohort, of which only 5% developed
ncident valve calcification. This restriction also hin-
ers the ability to fully characterize the apparent
onlinear relationship between %PredLVM and valve
alcification. Second is the limited data on duration
nd severity of hypertension, which precludes a more
obust adjustment for hypertension. Third is the
elatively modest relationship between %PredLVM
nd incident valve calcification. Despite these limita-
ions, the association between LVH, specifically con-
entric remodeling, and valve calcification has poten-
ially important clinical implications and warrantsGersh BJ, Siscovick DS. Association of
1
WP, et al. PrevalC O N C L U S I O N S
We found in the diverse MESA cohort that LVH
is associated with the prevalence and severity of
calcification of the aortic and mitral valves. More-
over, increased LV mass, specifically concentric
LVH, at baseline was associated with the risk of
incident AVC and MAC. These associations
were independent of hypertension or other ath-
erosclerotic risk factors, hs-CRP, IL-6, and sub-
clinical atherosclerotic disease, suggesting that
LVH might identify subjects at risk of developing
valve calcification. Further study is needed to
determine the pathophysiological links involved
and to evaluate their reversibility and impact on
patient outcomes.
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